Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A)

Charcot-Marie-Tooth neuropathy type 1A (CMT1A) is an inherited nerve disease that mainly affects the nerves in the arms and legs. These nerves are called peripheral nerves. In CMT1A, the outer covering of the nerve (called myelin) is damaged because of a change in a gene. This damage makes nerve signals slow and weak. Over time, this leads to weakness, thinner muscles, and loss of feeling in the feet, legs, hands, and arms. CMT1A is the most common form of Charcot-Marie-Tooth disease and is usually passed on in an autosomal dominant way (one changed gene from either mother or father is enough to cause it). MDPI+3PubMed+3Orpha+3

Charcot-Marie-Tooth neuropathy type 1A (CMT1A) is a genetic nerve disease. It is usually caused by an extra copy (duplication) of a gene called PMP22. This gene change damages the insulating “myelin” around peripheral nerves in the legs and arms. Over time, signals from brain to muscles and skin become slow and weak. People often develop foot deformity (high arch, hammer toes), weakness in feet and hands, balance problems, and sometimes burning or electric-shock pain. There is no cure yet, but many non-drug and drug treatments can reduce symptoms, protect function, and improve quality of life. PMC+2

Other names

Doctors and researchers may use several names for CMT1A. All of them describe the same or very similar conditions:

• Charcot-Marie-Tooth disease type 1A (CMT1A) – the most common name for this specific subtype. Medicover Genetics+1

• Charcot-Marie-Tooth neuropathy type 1A – stresses that this is a nerve (neuropathy) problem rather than a muscle problem. PMC+1

• Hereditary motor and sensory neuropathy type I (HMSN I) – CMT1A subtype – an older term meaning an inherited disease of movement (motor) and feeling (sensory) nerves. Clinical Actionability+1

• PMP22-related demyelinating neuropathy – points to the gene (PMP22) that is changed and the type of nerve damage (demyelination). PMC+2ScienceDirect+2

These names may sound different, but they all refer to the same basic disorder: a slowly progressive, inherited, demyelinating neuropathy caused mainly by changes in the PMP22 gene.

Types of CMT1A

CMT1A is one genetic type inside the large Charcot-Marie-Tooth group, but people with CMT1A can still look different from each other. Doctors sometimes describe “forms” or “patterns” based on age when symptoms start and how severe they are:

• Typical childhood-onset CMT1A
  This is the most common form. Children often start to have trouble running, jumping, or keeping up in school sports in late childhood or teenage years. They may develop high-arched feet and begin to trip or sprain ankles often. PMC+2Clinical Actionability+2

• Early-onset (infant or very young child) CMT1A
  In some children, low muscle tone, delayed walking, or clumsiness appear in the first years of life. These children may show more severe weakness and deformity earlier, but they still have the same genetic problem (PMP22 duplication). ScienceDirect+2MedLink+2

• Adult-onset mild CMT1A
  A few people have very mild symptoms that start in adulthood, such as slight foot weakness or mild balance problems. They may only be diagnosed when their children show clearer signs and genetic testing is done in the family. Epidemiology and Health System Journal+2BMJ Open+2

All of these forms share the same basic cause (extra copy of the PMP22 gene) and the same type of nerve damage, but the timing and severity of symptoms can be different from person to person, even inside the same family. Medicover Genetics+2Genomics Education Programme+2

Causes of CMT1A

For CMT1A, the main true cause is a genetic change in the PMP22 gene. When we talk about “causes” below, we include both the direct genetic cause and factors that explain how it appears in a person or family and what can make it better or worse.

1. PMP22 gene duplication (main cause)
   In most people with CMT1A, a small region on chromosome 17 that includes the PMP22 gene is copied twice (a “duplication”). This gives cells too much PMP22 protein, which harms myelin and leads to slow, weak nerve signals. MDPI+3Medicover Genetics+3Genomics Education Programme+3

2. Gene dosage effect of PMP22
   Myelin needs the right amount of PMP22. Too little causes another condition (HNPP), and too much causes CMT1A. This “dosage effect” means that even a normal-looking protein, when produced in excess, can disturb myelin structure and cause neuropathy. PMC+2ScienceDirect+2

3. Autosomal dominant inheritance in families
   CMT1A is usually autosomal dominant. A parent with CMT1A has a 50% chance of passing the changed PMP22 gene to each child. This family pattern explains why many relatives across generations show similar symptoms. MedlinePlus+3Medicover Genetics+3Epidemiology and Health System Journal+3

4. De novo (new) PMP22 duplication
   Sometimes, the PMP22 duplication appears for the first time in a child, even though neither parent has CMT1A. This is called a de novo mutation. The child can then pass it on to his or her own children. PubMed+2Nature+2

5. Disruption of compact myelin
   Extra PMP22 changes how myelin layers are built and kept stable. This causes myelin to break down, form abnormal structures, and lose its tight compact shape. The damaged myelin then slows or blocks nerve signal flow. PMC+2ScienceDirect+2

6. Chronic demyelination and remyelination cycles
   Over time, myelin gets damaged and rebuilt again and again. This leads to “onion bulb” structures around nerves and long-term scarring. These changes are a key part of the disease and explain the slow, progressive course. PMC+2ScienceDirect+2

7. Secondary axonal damage
   When myelin is damaged for many years, the core of the nerve fiber (the axon) can also degenerate. This worsens weakness and loss of feeling because axons are the main “wires” that carry signals. ScienceDirect+2Wikipedia+2

8. Modifier genes and genetic background
   People with the same PMP22 duplication can have different severity. Other genes that affect nerve repair, myelin health, or inflammation can modify how strong or mild the symptoms are. PubMed+2Epidemiology and Health System Journal+2

9. Age-related nerve vulnerability
   Nerves naturally change with age. In someone with CMT1A, age-related nerve wear adds on top of the inherited fragile myelin, so weakness and balance problems often slowly worsen over adult life. Wiley Online Library+1

10. Mechanical stress to already weak nerves
    Repeated ankle sprains, long standing, or ill-fitting shoes can place extra strain on already vulnerable peripheral nerves. This may not cause CMT1A on its own, but it can make symptoms like pain, deformity, and instability more obvious. Physiopedia+2Charcot-Marie-Tooth Association+2

11. Weight gain and low physical activity
    Extra body weight and weak muscles together make walking harder and increase fatigue. Lack of movement also reduces muscle strength and joint flexibility, which can worsen function in people who already have nerve damage. Physiopedia+2PMC+2

12. Nerve-toxic medicines (in susceptible people)
    Some medicines (for example, certain chemotherapy drugs) can damage nerves. In a person with CMT1A, these drugs may cause stronger side effects because their nerves are already fragile. Doctors often try to avoid such drugs when possible. Wikipedia+1

13. Diabetes or other acquired neuropathies added on top
    If someone with CMT1A also develops diabetes or another cause of nerve damage, the combined effect can lead to faster progression of numbness, pain, and weakness. Wikipedia+2ScienceDirect+2

14. Poor footwear and lack of orthotic support
    Walking without proper support in someone with weak ankles and high-arched feet can increase falls, joint strain, and deformities over time. Good braces and shoes help reduce this mechanical cause of worsening. PMC+3Charcot-Marie-Tooth Association+3Mayo Clinic+3

15. Untreated contractures and deformities
    When tight muscles and foot deformities are not managed early with therapy, splints, or surgery, joints may stiffen. This makes walking harder and further reduces activity, which feeds a cycle of weakness. Physiopedia+2PMC+2

16. Recurrent ankle injuries and falls
    Weak ankle muscles and poor balance can cause repeated sprains and falls. These injuries further weaken muscles, stretch ligaments, and cause fear of walking, adding to disability. CMT Research Foundation+2CMT Mod+2

17. Smoking and poor circulation
    Smoking and conditions that damage blood vessels may reduce blood flow to nerves and muscles. In a person with CMT1A, reduced circulation can worsen nerve function and healing after injury. ScienceDirect+1

18. Sleep problems and fatigue
    People with CMT often report poor sleep and fatigue. Low sleep quality and constant tiredness make it harder to exercise and stay active, which indirectly worsens weakness and balance. Epidemiology and Health System Journal+2MDPI+2

19. Psychological stress and low mood
    Chronic pain, limited mobility, and social challenges can lead to low mood or anxiety. This can reduce motivation to keep up with therapy or exercise, which again can worsen physical symptoms. Epidemiology and Health System Journal+2Muscular Dystrophy Association+2

20. Lack of access to early diagnosis and support
    When CMT1A is not diagnosed early, people may not get physical therapy, orthoses, or advice about safe activity. This delay can allow preventable complications like severe deformities and contractures to develop. Sequencing+3PMC+3Muscular Dystrophy Association+3

Symptoms of CMT1A

1. Difficulty running and frequent tripping
   One of the earliest signs is trouble running or keeping up with friends. Children or teens may seem clumsy, often stub their toes, or trip over small obstacles because they cannot lift the front of the foot well (foot drop). PMC+2Clinical Actionability+2

2. Weakness in feet and lower legs
   The small muscles in the feet and lower legs become weak. This makes it hard to lift the foot, push off the ground, or stand on tiptoe. The weakness is usually worse on both sides and slowly gets more noticeable over many years. ScienceDirect+2Clinical Actionability+2

3. High-arched feet (pes cavus)
   Many people with CMT1A develop very high arches. Tight muscles on one side of the foot and weak muscles on the other side pull the foot into an abnormal shape. This can make shoes uncomfortable and increase the risk of ankle sprain. ScienceDirect+2CMT Research Foundation+2

4. Hammer toes and other toe deformities
   Toes may bend at the joints and look curled (hammer toes). These deformities come from long-term imbalance between strong and weak muscles in the foot and can cause pressure sores or pain in shoes. ScienceDirect+2CMT Research Foundation+2

5. Thin (wasted) calf muscles
   Because the nerves cannot properly activate the muscles, the muscles shrink over time. The lower legs may look thin like an “inverted champagne bottle,” with skinny calves and relatively normal thighs. ScienceDirect+2Clinical Actionability+2

6. Weakness in hands and fingers
   As the disease progresses, the hands are often affected. People may struggle with tasks that need fine finger control, such as buttoning clothes, writing, or opening jars. Grip strength can become weaker. ScienceDirect+2CMT Research Foundation+2

7. Numbness and reduced feeling
   Many people notice numbness, reduced ability to feel light touch, or poor awareness of where their feet are in space. This loss of sensation makes balance worse and increases the risk of injury. PMC+2Clinical Actionability+2

8. Tingling, pins and needles, or burning pain
   Some people feel abnormal sensations such as tingling, “pins and needles,” or burning in the feet and hands. These feelings come from irritated or damaged sensory nerve fibers. PMC+2Wikipedia+2

9. Poor balance and unsteady walking
   Weak muscles, high arches, and loss of sensation together lead to unstable walking. People may sway, need to watch their feet carefully, or feel unsafe on uneven ground or in the dark. PMC+2MDPI+2

10. Reduced or absent reflexes
    Reflexes at the ankles and knees are often weak or missing when checked with a reflex hammer. This is a common sign of peripheral neuropathy in CMT1A. Clinical Actionability+2ScienceDirect+2

11. Fatigue and quick tiredness with walking
    Because muscles are weak and gait is inefficient, people with CMT1A may feel very tired after walking distances that other people find easy. This can limit school, work, or social activities. Epidemiology and Health System Journal+2Muscular Dystrophy Association+2

12. Cramps and muscle tightness
    Leg and foot muscles may cramp, especially after exercise or at night. Over time, muscles and tendons can shorten (contractures), making joints stiff and movement more limited. Physiopedia+2PMC+2

13. Scoliosis or spinal curvature in some people
    In some cases, weakness and imbalance of trunk muscles can lead to curvature of the spine (scoliosis). This is more common in childhood or teen years and may need monitoring by specialists. Wikipedia+1

14. Hand clumsiness and loss of dexterity
    When hand nerves are affected, fine tasks like typing, drawing, or using tools become slow and awkward. People may drop objects more often or feel they have “clumsy hands.” ScienceDirect+2CMT Research Foundation+2

15. Emotional and social impact
    Chronic pain, visible deformities, and use of braces or wheelchairs can affect self-esteem and mood. People may feel frustrated, anxious, or sad about limits in sports, work, or social life. Epidemiology and Health System Journal+2Muscular Dystrophy Association+2

Diagnostic tests for CMT1A

Doctors use many tests to diagnose CMT1A and to rule out other causes of neuropathy. Below they are grouped into physical exam, manual tests, lab and pathological tests, electrodiagnostic tests, and imaging tests.

Physical exam tests

1. General neurological examination
The doctor looks at muscle bulk, strength, sensation, reflexes, and coordination. In CMT1A they often see thin lower legs, high arches, weak foot and hand muscles, decreased reflexes, and sensory loss in a “stocking and glove” pattern. This exam gives the first strong clues that a hereditary neuropathy is present. Clinical Actionability+2ScienceDirect+2

2. Gait (walking) observation
The doctor watches how the person walks. Many people with CMT1A have a “steppage gait,” lifting their knees high to avoid tripping because of foot drop. They may also roll the foot outward due to high arches and unstable ankles. PMC+2CMT Research Foundation+2

3. Foot and lower limb inspection
The feet are checked for high arches, flat feet, claw toes, calluses, pressure sores, and ankle alignment. The legs are examined for muscle wasting. These visible changes strongly suggest a long-standing neuropathy such as CMT1A. ScienceDirect+2Muscular Dystrophy Association+2

4. Reflex testing with a hammer
Using a reflex hammer, the doctor checks knee and ankle reflexes. In CMT1A, these are often reduced or absent because the reflex arc depends on healthy sensory and motor nerves. Clinical Actionability+2ScienceDirect+2

Manual tests

5. Manual muscle testing
The examiner pushes against the person’s legs and arms in different directions to grade muscle strength. Weakness is usually greatest in the small muscles of the feet and hands. The pattern of weakness helps separate CMT1A from muscle diseases. ScienceDirect+2PMC+2

6. Heel-walk and toe-walk testing
The person is asked to walk on heels and then on toes. People with CMT1A often struggle to walk on heels because they cannot lift the front of the foot, and may also find toe-walking hard if calf muscles are weak. PMC+2Clinical Actionability+2

7. Balance tests (Romberg and single-leg stand)
The person stands with feet together and sometimes with eyes closed (Romberg test). They may sway or lose balance because of poor sensation in the feet. Single-leg stance shows how well ankle muscles and balance systems are working. MDPI+2Charcot-Marie-Tooth Disease+2

8. Sensory testing with soft touch and pin
The doctor lightly touches the skin with cotton, a blunt pin, or a small brush to check touch and pain sensation. In CMT1A, sensation is often reduced in the feet and hands compared to the trunk or upper arms. PMC+2Wikipedia+2

9. Vibration sense test with tuning fork
A vibrating tuning fork is placed on bony points such as the ankle or toe. People with CMT1A may feel the vibration weakly or not at all in the feet. This helps detect large-fiber sensory nerve damage. Clinical Actionability+2CMT Mod+2

Lab and pathological tests

10. Basic blood tests to rule out other causes
Doctors may order blood tests for diabetes, vitamin B12 deficiency, thyroid disease, kidney or liver problems, and autoimmune markers. These tests help rule out acquired causes of neuropathy so that inherited causes like CMT1A can be more confidently diagnosed. Wikipedia+2ScienceDirect+2

11. Genetic test for PMP22 duplication (core test)
The key diagnostic test is DNA testing that looks for duplication of the PMP22 gene. Methods such as PCR-based dosage assays, MLPA, or array CGH can detect the extra copy. A positive result confirms CMT1A in the right clinical context. Sequencing+3PMC+3Medicover Genetics+3

12. FISH (fluorescence in situ hybridization) for PMP22
In some labs, a FISH test is used. Special fluorescent probes bind to the PMP22 region, and under a microscope, an extra signal shows that there is a duplication. This method provides a visual confirmation of the genetic change. Baylor Genetics+1

13. Expanded CMT gene panel testing
If a clear PMP22 duplication is not found, or if the clinical picture is unusual, doctors may use gene panels that test many CMT-related genes at once. This helps distinguish CMT1A from other types such as CMT1B or CMT2. PubMed+2MDPI+2

14. Nerve biopsy (less common now)
In rare cases where genetic testing is inconclusive, a small piece of peripheral nerve (often from the lower leg) is removed and examined under a microscope. In CMT1A, the biopsy may show onion bulb formations from repeated demyelination and remyelination. Because it is invasive, this test is used less often now. PMC+2ScienceDirect+2

Electrodiagnostic tests

15. Nerve conduction studies (NCS)
Electrodes are placed on the skin, and small electrical pulses stimulate the nerves. In CMT1A, the speed of conduction is uniformly slow in many motor and sensory nerves, showing a demyelinating pattern. This test is central in identifying CMT1A. CMT Mod+3PMC+3ScienceDirect+3

16. Electromyography (EMG)
A very thin needle electrode is inserted into muscles to record electrical activity. EMG in CMT1A usually shows signs of chronic nerve damage with reduced recruitment of motor units, helping to confirm that weakness is due to neuropathy and not a primary muscle disease. ScienceDirect+2Wikipedia+2

17. F-wave and late response studies
Special nerve conduction responses called F-waves look at the full length of the motor nerve pathway. In CMT1A, F-wave latencies are prolonged, which supports a diagnosis of diffuse demyelinating neuropathy. ScienceDirect+2Wiley Online Library+2

18. Somatosensory evoked potentials (SSEPs) in selected cases
SSEPs measure how sensory signals travel from the limb to the brain. In some people with CMT1A, these signals are delayed, showing that both peripheral and sometimes central sensory pathways are affected. This test is used more in research or complex diagnostic cases. ScienceDirect+2Wikipedia+2

Imaging tests

19. X-rays of feet and spine
Plain X-rays can show bone changes due to long-standing muscle imbalance, such as high arches, hammer toes, ankle deformities, or scoliosis. Imaging helps surgeons and orthopedists plan braces or operations when needed. Muscular Dystrophy Association+2Mayo Clinic+2

20. MRI or ultrasound of peripheral nerves (in special centers)
In some specialized hospitals, MRI or high-resolution ultrasound can show thickened peripheral nerves or changes in muscle, supporting the diagnosis of a hereditary neuropathy. These imaging tools are usually adjuncts to, not replacements for, genetic testing and nerve conduction studies. ScienceDirect+2MedLink+2

Non-Pharmacological Treatments

Below are 20 important non-drug treatments for CMT1A. They do not change the gene, but they help you move better, stay safer, and live more independently. Always plan them with a neurologist, physiatrist, physical therapist, and occupational therapist. Dr.Oracle+4Charcot-Marie-Tooth Association+4PMC+4

1. Individualized Physical Therapy Program
   A regular physical therapy (PT) plan is one of the main treatments for CMT1A. The therapist teaches safe exercises to keep muscles as strong and flexible as possible. This usually includes strengthening of ankle, knee, hip, and core muscles; stretching of tight calves and hamstrings; and balance training. The purpose is to slow loss of strength, improve walking, and reduce falls. The mechanism is simple: repeated, carefully dosed training helps muscle fibers work better and keeps joints moving through a normal range of motion. Charcot-Marie-Tooth Association+2PMC+2

2. Stretching to Prevent Contractures
   Tight muscles and tendons can “freeze” joints into bad positions (contractures), especially around ankles and toes. Daily gentle stretching of calves, Achilles tendon, hamstrings, and fingers helps keep joints flexible. The purpose is to delay or prevent fixed deformities that later may need surgery. Stretching works by slowly lengthening muscles and connective tissues, improving blood flow, and reducing stiffness. It is usually done for several minutes, at least once or twice a day, under PT guidance at first, then at home. Charcot-Marie-Tooth Association+2PMC+2

3. Balance and Gait Training
   Because nerves are weak, people with CMT1A often trip or feel unsteady, especially in the dark or on uneven ground. Therapists use balance boards, tandem walking, obstacle courses, and safe fall-training to improve stability. The purpose is to reduce falls and increase confidence in walking. Mechanism: repeated practice trains the brain and remaining nerve fibers to use vision, inner-ear signals, and joint position sense more effectively, partly compensating for nerve damage. PMC+2Physiopedia+2

4. Low-Impact Aerobic Exercise
   Gentle aerobic activity such as walking on flat ground, cycling, or swimming helps heart and lungs and may reduce fatigue. The purpose is overall fitness, weight control, better mood, and healthier nerves. Mechanism: regular aerobic exercise improves blood flow to nerves and muscles, supports mitochondrial function, and can reduce inflammation and insulin resistance, all of which may support nerve health over time. Exercise must be paced to avoid over-fatigue and falls. PMC+1

5. Occupational Therapy for Hand and Daily Tasks
   Occupational therapists (OT) teach strategies and provide tools for weak hands and fingers. They may suggest built-up pens, special utensils, zipper pulls, and computer adaptations to make daily tasks easier. The purpose is to keep independence at school, work, and home. Mechanism: OT reduces the physical demand on weak muscles and teaches new movement patterns, so the person can still write, type, dress, cook, and use devices with less pain and effort. Charcot-Marie-Tooth Association+1

6. Ankle-Foot Orthoses (AFOs) and Supportive Footwear
   Many people with CMT1A have foot drop (difficulty lifting the front of the foot). Light plastic or carbon-fiber ankle-foot orthoses, high-top shoes, or custom insoles can lift the toes, stabilize the ankle, and reduce tripping. The purpose is safer walking and better alignment of foot and ankle. Mechanism: orthoses act like an external brace, replacing some of the lost muscle strength and helping to control abnormal movements during each step. PMC+2Physiopedia+2

7. Hand Splints and Wrist Supports
   For weak wrists and fingers, soft or rigid splints can keep joints in a more functional position. They are often used while writing, typing, or at night to prevent deformity. The purpose is to improve grip and reduce pain and fatigue in the hands. Mechanism: splints provide external support so that small hand muscles do not have to work as hard and joints stay in a neutral, less stressful position over time. Charcot-Marie-Tooth Association+1

8. Assistive Devices (Cane, Crutches, Walker)
   Some people with CMT1A need extra support for walking, especially on long distances or uneven surfaces. A cane, sticks, or a walker can reduce the load on weak ankles and knees and improve safety. The purpose is to lower fall risk and allow longer, more confident walking. Mechanism: these devices widen the base of support and give extra contact points with the ground, letting the arms help the legs keep balance. PMC+1

9. Home and School Fall-Prevention Modifications
   Simple changes at home or school can prevent accidents: removing loose rugs, adding grab bars in bathrooms, using night lights, and keeping pathways clear. The purpose is to reduce injury from falls, which are common when feet are weak and numb. Mechanism: environmental changes remove hazards and make it easier for a person with slower reflexes and weak muscles to move around safely. PMC+1

10. Energy Conservation and Fatigue Management
    Many people with CMT1A feel tired because weak muscles need extra effort to do everyday things. Therapists teach pacing, planning rest breaks, and using tools (e.g., wheeled bags instead of carrying heavy loads). The purpose is to save energy for important activities and reduce pain flares. Mechanism: better planning reduces repeated overuse of the same weak muscles and prevents “crash and burn” cycles of over-activity followed by severe fatigue. PMC+1

11. Pain Psychology, Cognitive Behavioral Therapy (CBT), and Relaxation
    Neuropathic pain can be constant and distressing. Pain psychologists use CBT, mindfulness, breathing exercises, and relaxation techniques to help people cope. The purpose is to reduce the emotional impact of pain and improve sleep and mood. Mechanism: CBT changes how the brain interprets pain signals, while relaxation lowers muscle tension and stress hormones, which can make pain feel less intense. PMC+2Springer Nature+2

12. Education and Genetic Counseling
    Because CMT1A is inherited, families often need clear information about the gene change, disease course, and future pregnancies. Genetic counselors explain the 50% transmission risk in autosomal dominant CMT1A, discuss testing options, and support family planning. The purpose is informed decision-making and emotional support. Mechanism: education reduces fear and confusion, and genetic counseling helps families understand realistic risks and available choices. ScienceDirect+1

13. Vocational and School Rehabilitation
    Work or school demands may be hard with weakness and fatigue. Vocational counselors and school resource teams can help adjust tasks, provide extra time, and modify workplaces. The purpose is to keep people with CMT1A employed and engaged in education. Mechanism: matching physical demands to abilities and providing assistive technology reduces strain and improves performance and participation. PMC+1

14. Respiratory and Sleep Assessment (in Advanced Cases)
    A small number of people with severe CMT1A may develop breathing muscle weakness or sleep-disordered breathing. Sleep studies and pulmonary function tests may be used. The purpose is early detection of low oxygen at night or reduced lung strength. Mechanism: if problems are found, non-invasive ventilation and breathing exercises can protect organs and improve daytime energy. ScienceDirect+1

15. Podiatry and Foot Care
    Numb, deformed feet are at high risk for calluses, sores, and infections. Regular visits to a foot specialist (podiatrist), careful nail cutting, and daily foot checks are very important. The purpose is to prevent ulcers and serious infections that could lead to hospitalization. Mechanism: early treatment of pressure spots and minor injuries stops them from progressing to deep wounds. Physiopedia+1

16. Weight Management and Nutrition Counseling
    Extra body weight makes it harder for weak muscles and joints to support the body and increases fatigue. A dietitian can design a healthy eating plan to reach or keep a healthy weight. The purpose is to reduce stress on feet, ankles, and knees and improve mobility and endurance. Mechanism: weight loss lowers joint load and may also improve metabolic health and blood flow to nerves. PMC+1

17. Peer Support Groups and Patient Organizations
    Talking with others who live with CMT1A helps people feel less alone. Patient organizations offer education, online forums, and local groups. The purpose is emotional support, sharing tips, and learning about new research and clinical trials. Mechanism: social support reduces anxiety and depression and can increase adherence to exercise and medical plans. Charcot-Marie-Tooth Association+2Charcot-Marie-Tooth Association+2

18. Assistive Technology and Smart Devices
    Voice-to-text software, ergonomic keyboards, and smart-home devices can make life easier when hands or legs are weak. The purpose is to reduce physical effort while communicating, studying, or working. Mechanism: technology replaces tasks that need fine hand control or quick walking, so a person can stay independent longer. PMC+1

19. Structured Clinical Follow-Up and Monitoring
    Regular visits with a neurologist or specialist CMT clinic allow tracking of strength, balance, pain, and breathing. The purpose is to adjust braces, therapy, and medicines at the right time. Mechanism: early detection of changes makes it easier to step up treatment before problems become severe or permanent. Dr.Oracle+1

20. Participation in Clinical Research Where Available
    For some people, joining a clinical trial (for example, studies of PXT3003 or new gene therapies) may be an option. The purpose is to gain access to potential new treatments and help advance science. Mechanism: carefully monitored experimental drugs try to correct PMP22 over-expression or protect nerves from further damage; participation is always voluntary and highly regulated. PubMed+4PMC+4ClinicalTrials+4

---

Drug Treatments

Important safety note: No medicine can cure CMT1A. Almost all drugs are used to treat neuropathic pain, cramps, mood problems, or sleep, not to fix the gene. Many are approved by the FDA for other neuropathic pain conditions and used “off-label” in CMT. Doses below are typical adult ranges from FDA labels or guidelines, not personal advice. Children and teens need different, weight-based doses. Never start, stop, or change a medicine without a neurologist. NCBI+8PMC+8Springer Nature+8

1. Gabapentin (Neurontin and others)
   Gabapentin is an anticonvulsant widely used for neuropathic pain. It binds to voltage-gated calcium channel subunits and reduces release of excitatory neurotransmitters, calming overactive pain pathways. Adults with neuropathic pain often start at low doses (for example 300 mg at night) and slowly increase, up to a usual total of 900–3600 mg per day in divided doses, as tolerated. Common side effects include dizziness, sleepiness, weight gain, and swelling of legs. The purpose is to reduce burning or shooting pain and improve sleep. Charcot-Marie-Tooth Association+4FDA Access Data+4FDA Access Data+4

2. Pregabalin (Lyrica, Lyrica CR)
   Pregabalin is similar to gabapentin but has more predictable absorption. It is FDA-approved for several neuropathic pain conditions and fibromyalgia. It reduces calcium-dependent release of pain-related neurotransmitters. Typical adult dosing for neuropathic pain starts around 150 mg per day in divided doses and may increase to 300–600 mg daily, depending on kidney function and tolerance. Side effects include dizziness, drowsiness, blurred vision, weight gain, and swelling. The purpose is to reduce constant nerve pain and improve quality of life. Charcot-Marie-Tooth Association+6FDA Access Data+6FDA Access Data+6

3. Duloxetine (Cymbalta)
   Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for depression, anxiety, and neuropathic pain. By boosting serotonin and norepinephrine in pain pathways, it helps the brain dampen pain signals. Adults often start at 30 mg once daily, increasing to 60 mg per day for pain conditions. Common side effects are nausea, dry mouth, sleep disturbance, and increased sweating. The purpose is mixed: pain relief and mood improvement in people with chronic nerve pain like in CMT1A. PMC+2Springer Nature+2

4. Venlafaxine (Effexor XR)
   Venlafaxine is another SNRI sometimes used when duloxetine is not suitable. It also increases serotonin and norepinephrine levels, strengthening the body’s own descending pain-control systems. Typical adult doses for pain are 75–225 mg per day, using extended-release forms. Possible side effects include increased blood pressure, nausea, insomnia, and sweating. The purpose is to treat both neuropathic pain and co-existing depression or anxiety that are common with chronic illness. PMC+2Springer Nature+2

5. Amitriptyline
   Amitriptyline is a tricyclic antidepressant (TCA) used at low doses for neuropathic pain and sleep problems. It blocks reuptake of serotonin and norepinephrine and also modulates sodium channels, quieting pain pathways. Adults often take 10–25 mg at night to start, increasing slowly up to around 50–75 mg if needed. Common side effects are dry mouth, constipation, blurred vision, daytime sleepiness, and weight gain; it can affect heart rhythm in some people. The purpose is to reduce night pain and improve sleep quality. PMC+2Springer Nature+2

6. Nortriptyline
   Nortriptyline is another TCA with similar effects but sometimes better tolerated in older adults. It also increases serotonin and norepinephrine and may have fewer sedating and anticholinergic side effects than amitriptyline. Adult dosing for neuropathic pain often starts at 10–25 mg at night and increases gradually under medical supervision. Side effects can include dry mouth, constipation, and changes in heart rhythm, so ECG monitoring may be advised in some patients. The purpose is chronic pain control with acceptable side effects. PMC+1

7. Carbamazepine
   Carbamazepine is an anticonvulsant and mood stabilizer that blocks voltage-gated sodium channels. It is classic first-line treatment for trigeminal neuralgia and sometimes used for shooting neuropathic pain in other conditions. Adult doses for pain often range from 200–1200 mg per day in divided doses. Side effects include dizziness, nausea, low sodium levels, and rare serious blood and liver problems. The purpose is to reduce severe sharp, shock-like pain in selected patients. PMC+1

8. Oxcarbazepine
   Oxcarbazepine is related to carbamazepine and also blocks sodium channels but may have a different side-effect profile. It is occasionally used when carbamazepine is not tolerated. Typical adult dosing begins around 300 mg twice daily, increasing slowly. Side effects include dizziness, double vision, and low sodium. The purpose is similar: to calm hyper-excitable nerve membranes that generate sudden pain spikes. PMC+2Springer Nature+2

9. Lamotrigine
   Lamotrigine is an anticonvulsant that acts on sodium channels and glutamate release. Evidence for neuropathic pain is less strong, but it may help in some complex cases or when mood stabilization is also needed. Adult doses must be increased very slowly over weeks to lower the risk of serious skin rash. Side effects include dizziness, headache, and skin reactions. The purpose is to provide another option when first-line drugs do not work or are not tolerated. PMC+1

10. Topical Lidocaine (5% Patch or Gel)
    Lidocaine patches or gels can be placed over small areas of focal neuropathic pain, such as a very painful foot region. They block sodium channels in local nerve endings and reduce pain signal generation without strong whole-body side effects. Patches are usually applied for up to 12 hours in a 24-hour period to intact skin. Side effects are usually mild skin irritation. The purpose is targeted relief of localized pain while limiting sedation. PMC+1

11. High-Strength Capsaicin Patch (8%)
    Capsaicin from chili peppers over-stimulates TRPV1 receptors on pain fibers, which then become less responsive for weeks. In specialized clinics, a high-dose patch is applied to painful areas for a short time under supervision. The purpose is long-lasting reduction in localized neuropathic pain. Mechanism: after initial burning feeling, the treated nerve endings lose some pain-transmitting chemicals and become less active. Side effects include temporary burning, redness, and increased pain during application. Springer Nature+1

12. Tramadol
    Tramadol is a weak opioid with SNRI-like effects, used as second-line treatment when first-line neuropathic pain drugs fail. Adult doses are commonly 50–100 mg every 6–8 hours as needed, up to a daily maximum set by guidelines. It acts on opioid receptors and inhibits serotonin and norepinephrine reuptake. Side effects include nausea, dizziness, constipation, and risk of dependence, seizures, and serotonin syndrome when combined with other drugs. It is usually reserved for short-term or rescue use. PMC+2Springer Nature+2

13. Tapentadol
    Tapentadol is a stronger painkiller that combines μ-opioid receptor activity with norepinephrine reuptake inhibition. It can be used for severe chronic neuropathic pain under specialist care. Adult doses vary depending on formulation and must follow label instructions. Side effects include nausea, constipation, dizziness, and dependence risk. The purpose is to control otherwise unmanageable pain, but because of safety concerns it is not a first choice. PMC+1

14. NSAIDs (Ibuprofen, Naproxen, etc.)
    Non-steroidal anti-inflammatory drugs (NSAIDs) are not very effective for pure nerve pain, but they can help with muscle and joint pain due to abnormal walking and deformity. They inhibit cyclo-oxygenase enzymes and reduce prostaglandin production, decreasing inflammation. Typical adult doses (for example, ibuprofen 400–600 mg every 6–8 hours with food) must respect maximum daily limits and kidney, stomach, and heart risks. Side effects include stomach upset, ulcers, and kidney strain. PMC+1

15. Paracetamol (Acetaminophen)
    Acetaminophen is often used as a basic background pain reliever. It works mainly in the central nervous system to lower pain and fever, though its exact mechanism is still being studied. Typical adult maximum is 3000–4000 mg per day, but lower limits are used in liver disease. It does not treat neuropathic pain strongly, but can reduce additional musculoskeletal pain with fewer stomach side effects than NSAIDs. Overdose can seriously damage the liver. PMC+1

16. Baclofen
    Baclofen is a muscle relaxant that activates GABA-B receptors in the spinal cord, decreasing reflex muscle contractions. In CMT1A, it may help painful muscle cramps or spasticity-like symptoms. Adult doses usually start low (5–10 mg three times daily) and increase slowly. Side effects include drowsiness, dizziness, and weakness; sudden stop can cause withdrawal symptoms. The purpose is to ease cramps and improve comfort, especially at night. Charcot-Marie-Tooth Association+2PMC+2

17. Tizanidine
    Tizanidine is another muscle relaxant that acts as an α2-adrenergic agonist, reducing excitatory signals to motor neurons. It may be used if baclofen is not effective or tolerated. Adult doses start very low (2–4 mg) and increase slowly. Side effects include low blood pressure, sleepiness, dry mouth, and liver test changes. The purpose is to lessen muscle tightness and spasms and improve sleep and function. PMC+1

18. PXT3003 (Investigational Combination of Baclofen, Naltrexone, and D-Sorbitol)
    PXT3003 is an experimental oral combination being studied specifically for CMT1A. It uses very low doses of baclofen, naltrexone, and D-sorbitol to reduce PMP22 over-expression and improve nerve function. Early phase 2 and 3 trials showed acceptable safety and signals of improved disability scores compared with placebo. Doses and schedules are set only inside clinical trials. Side effects have included mild dizziness, gastrointestinal upset, and fatigue. It is not yet an approved treatment outside research. PubMed+4PMC+4ClinicalTrials+4

19. Drugs for Anxiety and Depression (e.g., SSRIs)
    Living with a lifelong nerve disease can lead to anxiety and depression. Selective serotonin reuptake inhibitors (SSRIs) such as sertraline or escitalopram do not directly treat nerve damage but help mood, sleep, and pain coping. Doses depend on age and individual factors. Side effects include nausea, sleep changes, and sexual side effects. The purpose is to support mental health, which is a key part of pain control and quality of life. PMC+1

20. Sleep Medicines (Short-Term, Carefully Used)
    Severe night pain or cramps sometimes disrupt sleep. In selected, closely monitored cases, doctors may use short-acting sleep medicines (like certain “Z-drugs” or low-dose sedating antidepressants). These do not treat CMT1A itself but give short-term rest while other treatments are optimized. Side effects include daytime drowsiness, confusion, and dependence risk. The goal is to break a bad cycle of pain and insomnia while continuing non-drug therapy and safer long-term pain medicines. PMC+2Springer Nature+2

---

Dietary Molecular Supplements

Evidence for supplements in CMT1A is limited and mostly indirect (from studies in other neuropathies). They should never replace standard care. Always ask a doctor before starting them, especially if you take other medicines. PMC+2Charcot-Marie-Tooth Association+2

1. Alpha-Lipoic Acid – An antioxidant that supports mitochondrial function and has shown benefit in some diabetic neuropathy studies. Typical adult doses in studies are around 300–600 mg per day. It may reduce oxidative stress in nerves and improve microcirculation. Side effects can include nausea and skin rash.

2. Omega-3 Fatty Acids (EPA/DHA) – Found in fish oil, they have anti-inflammatory and membrane-stabilizing effects. Doses for general heart and nerve health often range from 1–3 g of combined EPA/DHA daily. They may support nerve cell membranes and reduce low-grade inflammation.

3. Vitamin D – Important for bone and muscle health. Many people are deficient. Supplement doses vary with blood levels (often 800–2000 IU daily, sometimes higher under supervision). Adequate vitamin D may improve muscle function and reduce falls.

4. Vitamin B12 – Essential for myelin formation. Deficiency can worsen neuropathy. In deficient people, doctors may use oral 1000 µg daily or injections. Correcting deficiency may improve nerve conduction and sensation.

5. Folate (Vitamin B9) – Works with B12 in one-carbon metabolism and myelin support. Supplements of 400–800 µg daily are common if diet is poor or levels are low.

6. Acetyl-L-Carnitine – Supports mitochondrial energy production. Some small studies in neuropathy suggest modest pain relief at doses like 1000–2000 mg per day. It may improve nerve regeneration by providing energy and protecting mitochondria.

7. Coenzyme Q10 – Another mitochondrial cofactor and antioxidant. Doses in studies often range from 100–300 mg daily. It may support energy production in nerve and muscle cells, though direct CMT1A data are limited.

8. Magnesium – Important for muscle relaxation and nerve signaling. Gentle supplementation (for example 200–400 mg elemental magnesium per day) may help cramps in some people if kidney function is normal.

9. Curcumin (Turmeric Extract) – Has anti-inflammatory and antioxidant effects. Standardized extracts at 500–1000 mg per day with piperine for absorption are often used in studies. It might reduce inflammatory contributions to pain, though data in CMT are lacking.

10. Resveratrol or Polyphenol-Rich Extracts – Plant antioxidants found in grapes and berries. They may reduce oxidative stress and improve microcirculation. Dosing varies widely; long-term safety at high doses is still under study.

---

Experimental Immunity-Boosting and Regenerative / Stem Cell–Related Drugs

Right now, no immune booster, regenerative drug, or stem cell therapy is approved as a standard treatment for CMT1A. All approaches below are experimental and available only in research settings. Doses are determined inside trials and are not for self-use. ScienceDirect+4PMC+4ClinicalTrials+4

1. Gene-Silencing Therapies Targeting PMP22 (Antisense or siRNA)
   These strategies use small pieces of genetic material to lower the extra PMP22 protein that causes CMT1A. The purpose is disease modification, not just symptom relief. Mechanism: antisense oligonucleotides or siRNA bind PMP22 mRNA and trigger its breakdown, reducing the toxic protein level in Schwann cells.

2. Viral Vector Gene Therapy
   Some preclinical studies use adeno-associated virus (AAV) vectors carrying genetic tools to correct PMP22 imbalance or support myelin. The purpose is long-term correction of the basic defect. Mechanism: the virus delivers the therapeutic gene to Schwann cells, which then produce helpful proteins for myelin repair.

3. Neurotrophin-Based Drugs (e.g., NT-3 Approaches)
   Neurotrophins are growth factors that support nerve survival and myelination. Experimental therapies aim to deliver more NT-3 or similar molecules to peripheral nerves. Mechanism: these factors bind receptors on nerves and Schwann cells, promoting growth, myelin maintenance, and regeneration.

4. Mesenchymal Stem Cell (MSC) Therapies
   In some early-phase trials in other neuropathies, MSCs from bone marrow or fat are infused or injected near nerves. The idea is that they release growth factors and anti-inflammatory molecules. Mechanism: paracrine signaling from MSCs may protect nerve fibers, reduce inflammation, and support repair, even if cells do not directly turn into nerve cells.

5. Schwann Cell–Derived or Neural Progenitor Cell Therapies
   These approaches use cells that are closer relatives of myelinating cells. They are delivered around damaged nerves to improve remyelination. Mechanism: transplanted cells may integrate into nerve sheaths and produce new myelin, or at least release helpful growth factors.

6. Immune-Modulating Biologic Drugs (Conceptual)
   Because CMT1A is not mainly an autoimmune disease, strong immune-suppressing biologics are not standard. However, some research explores mild immune modulation and inflammation control as supportive strategies. Mechanism: targeting inflammatory pathways that worsen nerve damage could theoretically slow progression, but firm evidence is lacking.

---

Surgical Treatments

Surgery in CMT1A does not fix the nerve problem. It corrects structural deformities that cause pain, pressure points, or major walking problems. Decisions are made by experienced orthopedic surgeons working with neurologists. PMC+2Physiopedia+2

1. Foot Deformity Correction (Cavovarus Reconstruction)
   People with CMT1A often develop high arches and inward-turned heels (cavovarus feet). Surgery can include bone cuts (osteotomies), tendon lengthening, and tendon transfers to balance muscles. The goal is to create a more plantigrade (flat) foot to improve walking and reduce pressure sores.

2. Tendon Transfer for Foot Drop
   In tendon transfer surgery, a stronger working tendon (for example, from a toe extensor) is moved to take over the job of the weak ankle dorsiflexor muscle. The purpose is to lift the foot during walking without always relying on an AFO.

3. Joint Fusion (Arthrodesis) in Severe Deformity
   If joints are very unstable or painful, surgeons may fuse them in a better position. This removes movement but can make standing and walking more stable. It is usually reserved for very advanced deformity when other options fail.

4. Correction of Hammer Toes and Toe Clawing
   Small surgeries on toes (soft-tissue release, bone trimming, or fusion) can relieve shoe pressure and prevent ulcers. The purpose is pain relief and easier shoe fitting.

5. Spinal Surgery for Severe Scoliosis
   Some people develop scoliosis or spinal deformity due to muscle imbalance. In rare severe cases, spinal fusion or other procedures are needed to protect lung function and reduce pain.

---

Prevention and Protection

You cannot prevent the genetic cause of CMT1A, but you can reduce complications and slow function loss: PMC+2Physiopedia+2

1. Avoid known nerve-toxic drugs (for example, certain chemotherapy drugs, high-dose metronidazole) whenever possible, and always remind doctors you have CMT.

2. Do not smoke, and limit alcohol, which can further damage peripheral nerves.

3. Maintain a healthy weight to reduce stress on weak feet and ankles.

4. Use proper footwear and orthoses early, before deformities become fixed.

5. Do daily stretching to keep ankles and toes flexible.

6. Check feet every day for blisters or wounds, especially if sensation is reduced.

7. Keep diabetes and other metabolic diseases under excellent control if present.

8. Keep vaccinations and general health checks up to date to reduce illness-related weakness.

9. Stay physically active with safe, low-impact exercise and avoid long bed rest.

10. Seek early therapy or counseling for mood problems so that depression does not stop you from exercising and caring for yourself.

---

When to See a Doctor

You should see a neurologist or your regular doctor regularly for monitoring, even if you feel stable. Go urgently or book an early visit if you notice faster-than-usual weakness, many new falls, sudden change in walking, new severe pain, foot wounds that do not heal, breathing or swallowing problems, or mood changes like persistent sadness or thoughts of self-harm. For new medications, supplements, or pregnancy planning, always talk with your neurologist first. Dr.Oracle+2ScienceDirect+2

---

What to Eat and What to Avoid

1. Eat a balanced diet rich in vegetables, fruits, whole grains, and lean protein to support muscles and nerves.

2. Eat enough protein from fish, eggs, beans, and lean meats to maintain muscle mass.

3. Eat healthy fats from olive oil, nuts, seeds, and fatty fish (omega-3s) to support cell membranes.

4. Eat foods rich in B-vitamins (leafy greens, legumes, fortified cereals) and consider supplementation if levels are low.

5. Eat calcium- and vitamin-D-rich foods (dairy, fortified plant milks, small fish with bones) for bones and muscles.

6. Avoid very high-sugar drinks and snacks that promote weight gain and diabetes, which can further damage nerves.

7. Avoid heavy alcohol use, as it is toxic to nerves and can worsen balance and falls.

8. Avoid extreme “fad” diets that sharply cut calories or major food groups; they can create deficiencies that hurt nerve health.

9. Avoid large amounts of processed meats and trans-fat-rich fast food, which promote inflammation.

10. Avoid unverified “miracle” supplements sold online; many lack evidence and can interact with medicines. PMC+2Charcot-Marie-Tooth Association+2

---

Frequently Asked Questions

1. Is CMT1A curable?
   No. At present there is no cure that removes the PMP22 gene duplication. Treatment focuses on rehabilitation, orthotics, pain control, and managing complications. Research on gene-targeted and disease-modifying drug therapy is active but still experimental. Clinical Trials Register+3Dr.Oracle+3ScienceDirect+3

2. Will I end up in a wheelchair?
   Many people with CMT1A can walk throughout life, especially if they use PT, braces, and safe exercise. Some need a wheelchair for long distances or later in life. Early and consistent rehab usually helps keep mobility for longer. PMC+2Physiopedia+2

3. Does exercise make CMT1A worse?
   Too much heavy exercise that causes repeated muscle injury is not good, but most moderate, low-impact exercise is helpful. A physical therapist can design a program that builds strength and endurance without over-fatigue. PMC+2Physiopedia+2

4. Can children and teenagers with CMT1A play sports?
   Often yes, with some changes. Low-impact activities like swimming or cycling are usually safer than contact sports or those that demand quick direction changes. Proper shoes, braces, and supervision are important. A pediatric neurologist and PT should guide choices. Charcot-Marie-Tooth Association+2PMC+2

5. Is pregnancy safe with CMT1A?
   Most women with CMT1A have normal pregnancies and healthy babies. Some notice temporary worsening of symptoms or new pain. Obstetricians and neurologists should plan delivery and pain management together. Genetic counseling is important because there is a 50% chance of passing on the gene change. ScienceDirect+1

6. Can CMT1A affect life span?
   For many people, life expectancy is near normal, especially with good care and prevention of complications. Severe forms or major breathing problems are less common. Regular follow-up helps detect any serious issues early. ScienceDirect+1

7. Are pain medicines always needed?
   No. Some people have mild or no pain and rely mainly on non-drug treatments. Others need long-term medication. The goal is the lowest dose of the safest medicine that gives acceptable pain control, combined with exercise, braces, and psychological support. PMC+2Springer Nature+2

8. What is the difference between CMT1A and other CMT types?
   CMT1A is a demyelinating form caused by PMP22 duplication. Other types can be axonal (affecting the nerve fiber core) or linked to different genes. Symptoms may look similar, but age of onset, speed of progression, and pattern of nerve conduction changes can differ. Genetic testing tells the exact type. ScienceDirect+1

9. Should my family members get genetic testing?
   This is a personal decision. Genetic counselors explain benefits and risks. Testing can confirm risk in relatives and help with family planning but may raise emotional, insurance, or privacy concerns depending on local laws. ScienceDirect+1

10. Do braces mean my legs are getting worse?
    No. Braces are tools, not signs of failure. Using AFOs early often prevents falls and joint damage and can delay the need for surgery. They help you move more, not less. PMC+2Physiopedia+2

11. Is it safe to have surgery with CMT1A?
    Most surgeries are safe when the anesthesia team knows about the neuropathy and avoids certain nerve-toxic drugs. Some people are more sensitive to nerve compression, so careful positioning is important. Orthopedic surgery for foot deformity can greatly improve function when timed well. PMC+2Physiopedia+2

12. Can supplements alone treat CMT1A?
    No. Supplements may support general nerve and muscle health but cannot fix the gene problem or replace PT, orthotics, or medicines. They should be seen as add-ons, not main treatment. PMC+2Charcot-Marie-Tooth Association+2

13. Are there new treatments coming soon?
    Research is active on PXT3003, gene-silencing, and gene therapy approaches. Some are in phase 3 trials. It will still take time to prove safety and benefit and get approvals. Patient organizations and clinical trial registries list current studies. ScienceDirect+5PMC+5ClinicalTrials+5

14. Can CMT1A cause hearing or vision problems?
    CMT mainly affects peripheral nerves for movement and touch, but in some cases, other nerves, including those to hearing or eye muscles, can be involved. If you notice hearing loss, ringing in the ears, or double vision, see an audiologist or eye specialist and inform your neurologist. ScienceDirect+1

15. What is the most important thing I can do right now?
    For most people, the best steps are: confirm diagnosis with a neurologist, start regular PT/OT, use orthoses if advised, follow a healthy lifestyle, and treat pain and mood problems early. Building a trusted care team and staying informed about new research will help you live as fully and safely as possible with CMT1A. ScienceDirect+5Charcot-Marie-Tooth Association+5PMC+5

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 24, 2025.